Overview

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Status:
Enrolling by invitation
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma SRL